US Food and Drug Administration (USFDA) has conducted a periodic cGMP inspection of Biocon’s Drug Substance manufacturing site at Bangalore Campus from September 17 - 21, 2018. After the inspection there was no observations found. The successful audit of this site reflects the company’s strong commitment to cGMP compliance.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.